Highlights

  • PYC Therapeutics received approval to escalate PYC-003 dosing to 2.4 mg/kg in a Phase 1b repeat-dose study.
  • The Safety Review Committee approved progression after reviewing early safety data from Phase 1a and Phase 1b cohorts.
  • An open-label extension study has been approved to collect longer-term safety and efficacy data for up to 24 months.
  • PYC reported that its 2026 Capital raising extended funding runway through to calendar 2030.

PYC Therapeutics (ASX:PYC) has received approval to increase dosing in its early-stage trial of PYC-003, an RNA-based therapy candidate being developed for autosomal dominant polycystic kidney disease (PKD).

The company announced on 22 July 2026 that an independent Safety Review Committee approved dose escalation to 2.4 mg/kg in the Phase 1b repeat-dose study after reviewing safety information from earlier cohorts.

The decision allows PYC-003 development to continue toward higher dose levels while the company collects additional safety and efficacy information from patients with PKD.

What Was Announced?

PYC-003 is being evaluated through linked Phase 1a and Phase 1b studies.

The Phase 1a Single Ascending Dose (SAD) study is assessing increasing dose levels in healthy or early-stage PKD volunteers, while the Phase 1b Multiple Ascending Dose (MAD) study is evaluating repeat dosing in PKD patients to assess safety and early efficacy indicators over time.

The Safety Review Committee approved continued Phase 1a escalation up to 4 mg/kg and progression of the Phase 1b study to 2.4 mg/kg.

The decision was based on four weeks of safety follow-up from the Phase 1a cohort receiving 2.4 mg/kg and safety data from the first three patients in the Phase 1b cohort receiving 1.2 mg/kg.

PYC has also indicated a potential additional Phase 1b cohort at either 0.4 mg/kg or 4 mg/kg depending on emerging dose-response information.

An Open-Label Extension (OLE) study has been approved, allowing eligible patients to continue PYC-003 treatment for up to 24 months.

Why This Matters

For PYC Therapeutics (ASX:PYC), successful dose escalation represents an important clinical development step because it allows the program to test higher doses that may provide more information on potential therapeutic activity.

PYC-003 is designed as an RNA-targeting therapy intended to address genetic drivers associated with cyst growth in PKD rather than only managing symptoms.

However, dose escalation approval confirms safety observations only and does not demonstrate clinical effectiveness. The ability of PYC-003 to influence disease progression will require future efficacy data.

The 24-month open-label extension also provides an opportunity to collect longer-term information, which may be important in a chronic condition such as PKD where changes in disease markers can take time to assess.

Company Background

PYC Therapeutics (ASX:PYC) is a clinical-stage RNA therapeutics company focused on rare genetic diseases affecting the eye and kidney.

The company's lead program, VP-001, targets retinitis pigmentosa type 11 (RP11), an inherited retinal disease associated with PRPF31 gene mutations.

PYC-003 is the company's kidney disease program, using its RNA-based platform to target genetic drivers involved in autosomal dominant polycystic kidney disease.

The company has stated that it is progressing four RNA therapy programs across genetic eye and kidney indications.

Financial Position

PYC strengthened its Balance Sheet in early 2026 through a capital raising involving an institutional Placement and entitlement offer.

The company secured approximately A$537 million in institutional commitments, followed by a retail entitlement offer that increased total proceeds toward A$600 million.

The Offer Price was A$1.50 per share.

PYC stated that the funding extended its cash runway through to calendar 2030 and was intended to support development of its four drug programs through key clinical milestones.

The Phase 1b announcement did not disclose an updated cash balance or quarterly cash burn.

What Comes Next?

The next major milestone for PYC (ASX:PYC) is Phase 1a SAD safety and efficacy data for PYC-003, which the company expects in the second half of 2026.

Further important data will come from the Phase 1b MAD study and the Open-Label Extension, with results expected during 2027.

Investors will also monitor additional Safety Review Committee decisions as dosing progresses and any regulatory discussions with the U.S. Food and Drug Administration (FDA) regarding future development pathways.

Updates from the VP-001 retinal disease program will also remain relevant to the company's broader pipeline.

Risks

PYC (ASX:PYC) remains exposed to early-stage clinical development risks, including potential safety issues at higher doses or failure to demonstrate meaningful efficacy despite acceptable tolerability. PKD is a slow-progressing condition, which may require extended follow-up periods to assess treatment impact. The company remains pre-revenue and dependent on clinical execution across multiple programs, although its recent capital raising provides extended funding capacity. Regulatory pathways for future studies may also change depending on ongoing discussions with regulators.

Investor Takeaway

The approval to escalate PYC-003 dosing is an incremental clinical milestone that confirms the program has progressed through early safety assessments without requiring a halt or redesign.

The decision allows PYC Therapeutics (ASX:PYC) to continue evaluating higher dose levels and collect longer-term patient data through the approved open-label extension.

The more significant milestones remain the Phase 1a data expected in 2026 and Phase 1b/OLE results expected in 2027, which will provide further insight into whether PYC-003 can demonstrate a meaningful therapeutic effect.